Representative imageJapanese drug firm Takeda Biopharmaceuticals has received market authorisation from the Drug Controller General of India (DCGI) for QDENGA, making it the first dengue vaccine approved here. The vaccine is designed to protect against all four dengue virus serotypes and for individuals 4 to 60 years of age, says a company statement.QDENGA can be used in individuals regardless of previous dengue exposure, without the need for pre-vaccination testing. TOI had broken the story regarding the vaccine launch in April last year.It is a tetravalent, live-attenuated vaccine designed to provide protection across all four dengue virus serotypes. The vaccine is administered subcutaneously 0.5 mL as a two-dose regimen, with doses given three months apart.QDENGA has been approved in 43 countries across Asia, Latin America and Europe, including India, with over 32 million doses distributed globally through public and private programs.India accounts for nearly one-third of the global dengue burden. In 2025, reported cases exceeded 113,000, but modelling analyses suggest the dengue burden in India appears to be higher than reported, likely representing tens of millions of infections each year.
Japanese firm’s dengue vaccine becomes first to get regulatory approval in India
Japanese drug firm Takeda Biopharmaceuticals has received market authorisation from the Drug Controller General of India (DCGI) for QDENGA, making it the first dengue vaccine approved here. The vaccine is designed to protect against all four dengue virus serotypes and for individuals 4 to 60 years of age, says a company statement.
179 words~1 min read
